Who owns RECURSION PHARMACEUTICALS, INC. (RXRX)? Elite investor 13F holders

2 tracked elite investors reported holding RECURSION PHARMACEUTICALS, INC as of 2026-06-30, including D.E. Shaw, Bridgewater Associates. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.

2 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences

Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial…

Reported holders and securities, including exits (up to 20)

Reported holders and securities, including exits (up to 20)
InvestorSecurityInstrumentReport periodFiledValueQuantityUnitsChangeSource
Renaissance Technologies LLCRecursion Pharmaceuticals InSHARE2026-06-302026-08-13 00:00:000.00 USD0.000000SharesexitedOriginal filing
Tudor InvestmentRecursion Pharmaceuticals InSHARE2026-06-302026-08-14 00:00:000.00 USD0.000000SharesexitedOriginal filing
D.E. ShawRecursion Pharmaceuticals InSHARE2026-06-302026-08-14 00:00:00139144.00 USD37914.000000SharesreduceOriginal filing
Bridgewater AssociatesRecursion Pharmaceuticals InSHARE2026-06-302026-08-14 00:00:00138238.00 USD37667.000000SharesbuyOriginal filing

Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.

This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.

How to read the data · Disclaimer

Read as Markdown